Financial disclosures

Size: px
Start display at page:

Download "Financial disclosures"

Transcription

1 Financial disclosures Named co-inventor on PCT applications CH2012/ and PCT2014/CH Chief Scientific Officer EMAGine SA

2 Historical decision in Future: extremely thin corneas Dresden ( 3 mw/cm 2 for 30 min) = 330 µm effect Recommendation: only treat if 400 µm 300 µ Wollensak et al., 1998 Seiler & Hafezi, 2006

3 Treat thin corneas 1. Future: extremely thin corneas JCRS, 2009

4 Other techniques 1. Future: extremely thin corneas Hypoosmolar CXL Contact-lens-assisted Transepithelial CXL Epithelial island CXL

5 Modify depth of effect 1. Future: extremely thin corneas Modify Modify Riboflavin Modify UV Thickness concentration intensity Hypoosmolar CXL Transepithelial CXL Contact-lens-assisted Epithelial island CXL

6 New model 1. Future: extremely thin corneas Modify UV intensity Riboflavin diffusion kinetics Oxygen diffusion kinetics

7 Fixed fluence (5.4 J/cm 2 ) 1. Future: extremely thin corneas 400 µm 300 µm

8 Fixed fluence (5.4 J/cm 2 ) 1. Future: extremely thin corneas 400 µm 300 µm Hypoosmolar Contact lens-assisted

9 Adapted fluence 1. Future: extremely thin corneas 400 µm 300 µm 250 µm 3 mw/cm 2 for 30 3 mw/cm 2 for xx 3 mw/cm 2 for xx 5.4 J/cm 2 xx J/cm 2 xx J/cm 2

10 New model to adapt CXL effect between 1. Future: extremely thin corneas Kling & Hafezi., JRS, in press

11 Treat corneas thinner between 200 and 400 µm 1. Future: extremely thin corneas Currently 32 eyes Depth of demarcation line at 1 month Treated so far: 270 µm to 395 µm

12 Simplified protocol 1. Future: extremely thin corneas 1. Perform abrasio 2. Instill riboflavin with speculum in place 3. Measure thickness after hypoosmolar riboflavin installation 4. Adapt the total fluence and treat

13 Conclusions 1. Future: extremely thin corneas The future: customized settings for every corneal thickness Use one single riboflavin solution: no more confusion with multiple different riboflavin solutions Can the CXL effect stabilize a 250 µm cornea?

14 AMR (Antimicrobial resistance), a global problem

15 AMR, a global problem ANTIMICROBIAL RESISTANCE Global Report on surveillance 2014 What you need to know WHO s first global report on antimicrobial resistance, with a focus on antibiotic resistance, reveals that it is no longer a prediction for the future. Antibiotic resistance - when bacteria change and antibiotics fail - is happening right now, across the world The report is the most comprehensive picture to date, with data provided by 114 countries Looking at 7 common bacteria that cause serious diseases from bloodstream infections to gonorrhoea High levels of resistance found in all regions of the world Significant gaps exist in tracking of antibiotic resistance Over the last 30 years, no major new types of antibiotics have been developed Penicillin Cephalosporin Carbapenem Fluoroquinolones Discovery void What does this mean? Without urgent action we are heading for a post-antibiotic era, in which common infections and minor injuries can once again kill What you can do Use antibiotics only when prescribed by a health professional How can infections be prevented in the first place to reduce the need for antibiotics? Better hygiene Complete the full prescription, even if you feel better Access to clean water and sanitation Infection control in healthcare facilities Vaccination Never share antibiotics with others or use leftover prescriptions More information at WHO report 2014

16 with a focus on antibiotic resistance, reveals that it is no longer a prediction for the future. Antibiotic resistance - when bacteria change and antibiotics fail - is happening right now, across the world The report is the most comprehensive picture to Looking at 7 common bacteria that cause serious High levels of resistance found in all Significant gaps exist in tracking of date, with data provided by diseases from bloodstream regions of the world antibiotic resistance 114 countries infections to gonorrhoea Over the last 30 years, no major new types of antibiotics have been developed Discovery void Penicillin Cephalosporin Carbapenem Fluoroquinolones What does this mean? Without urgent action we are heading for a post-antibiotic era, in which common infections and minor injuries can once again kill How can infections be prevented in the first place to reduce the need for antibiotics? Better Access to Infection control Vaccination hygiene clean water in healthcare and sanitation facilities What you can do Use antibiotics only when prescribed Complete the full prescription, Never share antibiotics with others

17 AMR, a global problem

18 AMR, a global problem

19 Diagnostic dilemma, therapeutic dilemma

20 Major geographic variations Whitcher et al., Int Ophthalmol Clin 2002

21 1. Introduction 2. Problem

22 Problem Treatment success depends on time/access to vision care specialists type of treatment funding compliance

23 Scenario 1 + AB +

24 Scenario 2 24h 72h CDVA 20/200

25 Zurich, Switzerland: 2004 IROC (Seiler, Mrochen, Hafezi, Iseli) ETH Swiss Federal Institute of Technology

26 Cross-Linking effects 32 Steric hindrance 3 DNA/RNA intercalation 4 Oxidative stress

27 UV-A + riboflavin = disinfectant Goodrich et al, 2000, Vox Sang Reddy et al, 2008, Transfusion Med Rev Heaselgrave et al., Appl Environ Microbiol, 2010

28 2008. Switzerland. Proof of principle. 2. First Results Post-LASIK keratitis Ten days after PACK-CXL Iseli et al, 2008, Cornea

29 PACK-CXL Hafezi et al, Journal of Refractive Surgery, Need gap: AMR 3. Need gap: Corneal infection 4. Alternative: PACK- Cross-Linking Kills both bacteria and fungi Reduce diagnostic and therapeutic dilemma Alternative to antibiotics

30 Laboratory Staph aureus growth inhibition by 97% in 30 minutes (Dresden keratoconus protocol) 2. First Results Schrier et al., IOVS,2008 Martins et al., IOVS, 2008

31 Veterinary ophthalmology. 2. First Results 1 dy 13 dys 3 mo Pot and Hafezi, Vet Ophthalmol, 2013 Mortensen et al., Vet Ophthalmol, 2013

32 2011 Phase 2 Clinical Trial No antibiotics 2. First Results Before PACK-CXL Two weeks after PACK-CXL Makdoumi et al., Curr Eye Res, 2011

33 Kill bacteria and fungi simultaneously BACTERIA Up to 98% in vitro With fluence currently used in clinical setting 2. Results 3. Optimize FUNGI 60-70% in vitro With high fluence currently used in clinical setting (7.2 J/cm 2 ) MSSA MRSA P. aeruginosa S. epidermidis C. albicans Fusarium 5.4 J/cm 2 ( ) ( ) 98% 99% 98% 97% 60-70% 60-70% Schrier et al., IOVS,2008 Martins et al., IOVS, 2008 Richoz et al., JRS, 2014 Richoz et al., unpublished data

34 Future treatment needs Optimize 2. Results Accelerate 3. Optimize Access to all

35 Simplify 2. Results 3. Optimize

36 : Early ulcers 2. Results JRS, Optimize Prospective clinical study 40 eyes. All stages of ulcer, 0-12 mm Bacterial, fungal, mixed Overall: 15% required additional treatment Early ulcers alone: none required additional treatment

37 : Early ulcers 2. Results 3. Optimize

38 : Advanced ulcers 2. Results 3. Optimize Ophthalmology, 2014 Prospective randomised clinical study 40 patients with therapy-resistant end-stage ulcer Bacterial, fungal, mixed Arm 1: Medication only, 21 eyes Arm 2: Medication plus CXL, 19 eyes Healing time comparable

39 : Advanced ulcers 2. Results 3. Optimize Ophthalmology, 2014

40 Treat Early Infiltrate / Early ulcer? Advanced ulcer? 2. Results 3. Optimize Price et al., JRS, 2012 Said et al., Ophthalmology, 2014

41 Accelerate 2. Results 3. Optimize For keratoconus? No Hammer et al, IOVS, 2014

42 Accelerate: bactericidal effect 2. First Results 3. Optimize 150 seconds, 98% killing Richoz et al, JRS, 2014

43 Phase 2 trial: accelerated PACK-CXL mw/cm 2 2. Results 3. Optimize Arm 1: antibiotics alone (n=28) Arm 2: antibiotics & CXL (n=32) Difference in healing 12 vs 7 days (p=0.001) Knyazer et al., in preparation

44 Phase 2 trial: accelerated PACK-CXL mw/cm 2 2. Results 3. Optimize Arm 1: antibiotics alone (n=28) Arm 2: antibiotics & CXL (n=32) Difference in healing 12 vs 7 days (p=0.001) Knyazer et al., in preparation

45 Swiss PACK-CXL RCT Phase 3 prospective RCT Non-inferiority study Infiltrates and small ulcers < 4 mm, < 350 µm depth 2. First Results 3. Optimize 4. Clinical data 13 sites 10 countries

46 Introduction at ESCRS 2016 Copenhagen 2. First Results 3. Optimize 4. Clinical data 5. CXL at the slit lamp C-Eye device

47 Introduction at ESCRS 2016 Copenhagen 2. First Results 3. Optimize 4. Clinical data 5. CXL at the slit lamp C-Eye device

48 C-Eye device Sterile tip Intensities delivered 2. First Results 3 mw/cm 2 9 mw/cm 2 18 mw/cm 2 30 mw/cm 2 Keratoconus Corneal Ulcer 3. Optimize 4. Clinical data 5. CXL at the slit lamp Beam optimization Safety mechanism

49 C-Eye Device 1 2. First Results 3. Optimize 2 4. Clinical data 5. CXL at the slit lamp 3 PACK-CXL EMAGine s product line offers a one-time treatment using basic equipment and infrastructure of any vision care specialist.* The use of UV light and a proprietary chromophore solution would be effective in killing all harmful pathogens in one treatment, including mixed infections. * Prophylatic anti-microbials can be administered after treatment.

50 Benefits Current PACK-CXL + 2. First Results 3. Optimize ( ) 4. Clinical data 5. CXL at the slit lamp Compliance-independent approach Diagnostic-independent approach

51 Why do PACK-CXL, antibiotics are cheap In the future: antimicrobial resistance will increase 2. First Results PACK-CXL does not only kill, but increases resistance to digestion = lesser scar 3. Optimize 4. Clinical data 5. CXL at the slit lamp Many areas of the world: doctor s costs are limiting PACK-CXL independent of diagnostic look and experience in infection assessment Less compliance issues

52

53 Zurich Mövenpick Hotel Nov 30 - Dec 2,

PACK-CXL. for infectious keratitis. Farhad Hafezi, MD PhD. Professor of Ophthalmology Keck School of Medicine USC Los Angeles, USA

PACK-CXL. for infectious keratitis. Farhad Hafezi, MD PhD. Professor of Ophthalmology Keck School of Medicine USC Los Angeles, USA PACK-CXL for infectious keratitis Farhad Hafezi, MD PhD Professor of Ophthalmology University of Geneva Geneva, Switzerland Medical Director ELZA Institute Zurich, Switzerland Research Group Leader Lab.

More information

Horses treated by PACK-CXL

Horses treated by PACK-CXL Horses treated by PACK-CXL Anna Hellander Edman, Jes Mortensen & Björn Ekesten Zurich December 2014 Jes Mortensen,MD Sweden 0 Autumn 2009 the first keratitis in a horse was treated by PACK-CXL by our group

More information

WHO s first global report on antibiotic resistance reveals serious, worldwide threat to public health

WHO s first global report on antibiotic resistance reveals serious, worldwide threat to public health New WHO report provides the most comprehensive picture of antibiotic resistance to date, with data from 114 countries 30 APRIL 2014 GENEVA - A new report by WHO its first to look at antimicrobial resistance,

More information

Clinical Features, Antibiotic Susceptibility Profile, and Outcomes of Infectious Keratitis Caused by Stenotrophomonas maltophilia

Clinical Features, Antibiotic Susceptibility Profile, and Outcomes of Infectious Keratitis Caused by Stenotrophomonas maltophilia Clinical Features, Antibiotic Susceptibility Profile, and Outcomes of Infectious Keratitis Caused by Stenotrophomonas maltophilia Sotiria Palioura, MD, MSc, PhD Cornea & External Disease Specialist Athens

More information

Study of Bacteriological Profile of Corneal Ulcers in Patients Attending VIMS, Ballari, India

Study of Bacteriological Profile of Corneal Ulcers in Patients Attending VIMS, Ballari, India International Journal of Current Microbiology and Applied Sciences ISSN: 2319-7706 Volume 5 Number 7 (2016) pp. 200-205 Journal homepage: http://www.ijcmas.com Original Research Article http://dx.doi.org/10.20546/ijcmas.2016.507.020

More information

How is Ireland performing on antibiotic prescribing?

How is Ireland performing on antibiotic prescribing? European Antibiotic Awareness Campaign 2016 November Webinar Series on Antibiotic Prescribing How is Ireland performing on antibiotic prescribing? Dr Rob Cunney National Clinical Lead HCAI AMR Clinical

More information

Antibiotic resistance is one of the biggest threats to global health, food security, and development today.

Antibiotic resistance is one of the biggest threats to global health, food security, and development today. Antibiotic resistance Fact sheet Updated November 2017 Key facts Antibiotic resistance is one of the biggest threats to global health, food security, and development today. Antibiotic resistance can affect

More information

The South African AMR strategy. 3 rd Annual Regulatory Workshop Gavin Steel Sector wide Procurement National Department of Health; South Africa

The South African AMR strategy. 3 rd Annual Regulatory Workshop Gavin Steel Sector wide Procurement National Department of Health; South Africa The South African AMR strategy 3 rd Annual Regulatory Workshop Gavin Steel Sector wide Procurement National Department of Health; South Africa Background to AMR 2 What is Antimicrobial stewardship and

More information

New Opportunities for Microbiology Labs to Add Value to Antimicrobial Stewardship Programs

New Opportunities for Microbiology Labs to Add Value to Antimicrobial Stewardship Programs New Opportunities for Microbiology Labs to Add Value to Antimicrobial Stewardship Programs Patrick R. Murray, PhD Senior Director, WW Scientific Affairs 2017 BD. BD, the BD Logo and all other trademarks

More information

Imagine. Multi-Drug Resistant Superbugs- What s the Big Deal? A World. Without Antibiotics. Where Simple Infections can be Life Threatening

Imagine. Multi-Drug Resistant Superbugs- What s the Big Deal? A World. Without Antibiotics. Where Simple Infections can be Life Threatening Multi-Drug Resistant Superbugs- What s the Big Deal? Toni Biasi, RN MSN MPH CIC Infection Prevention Indiana University Health Imagine A World Without Antibiotics A World Where Simple Infections can be

More information

Role of Moxifloxacin in Bacterial Keratitis

Role of Moxifloxacin in Bacterial Keratitis Original Article Role of Moxifloxacin in Bacterial Keratitis Aamna Jabran, Aurengzeb Sheikh, Syed Ali Haider, Zia-ud-din Shaikh Pak J Ophthalmol 29, Vol. 25 No. 2.................................................................................

More information

Review Article New Treatments for Bacterial Keratitis

Review Article New Treatments for Bacterial Keratitis Hindawi Publishing Corporation Journal of Ophthalmology Volume 2012, Article ID 831502, 7 pages doi:10.1155/2012/831502 Review Article New Treatments for Bacterial Keratitis RaymondL.M.Wong, 1 R. A. Gangwani,

More information

Burden of disease of antibiotic resistance The example of MRSA. Eva Melander Clinical Microbiology, Lund University Hospital

Burden of disease of antibiotic resistance The example of MRSA. Eva Melander Clinical Microbiology, Lund University Hospital Burden of disease of antibiotic resistance The example of MRSA Eva Melander Clinical Microbiology, Lund University Hospital Discovery of antibiotics Enormous medical gains Significantly reduced morbidity

More information

The pharmacological and microbiological basis of PK/PD : why did we need to invent PK/PD in the first place? Paul M. Tulkens

The pharmacological and microbiological basis of PK/PD : why did we need to invent PK/PD in the first place? Paul M. Tulkens The pharmacological and microbiological basis of PK/PD : why did we need to invent PK/PD in the first place? Paul M. Tulkens Cellular and Molecular Pharmacology Unit Catholic University of Louvain, Brussels,

More information

WORLD ANTIBIOTIC AWARENESS WEEK

WORLD ANTIBIOTIC AWARENESS WEEK # AntibioticResistance WORLD ANTIBIOTIC AWARENESS WEEK 14-20 NOVEMBER 2016 2016 CAMPAIGN TOOLKIT TABLE OF CONTENTS Why we need a global campagin... Campagin objectives... Key messages... Calls to action

More information

Healthcare Facilities and Healthcare Professionals. Public

Healthcare Facilities and Healthcare Professionals. Public Document Title: DOH Guidelines for Antimicrobial Stewardship Programs Document Ref. Number: DOH/ASP/GL/1.0 Version: 1.0 Approval Date: 13/12/2017 Effective Date: 14/12/2017 Document Owner: Applies to:

More information

Collecting and Interpreting Stewardship Data: Breakout Session

Collecting and Interpreting Stewardship Data: Breakout Session Collecting and Interpreting Stewardship Data: Breakout Session Michael S. Calderwood, MD, MPH Regional Hospital Epidemiologist, Dartmouth-Hitchcock Medical Center March 20, 2019 None Disclosures Outline

More information

Vaccination as a potential strategy to combat Antimicrobial Resistance in the elderly

Vaccination as a potential strategy to combat Antimicrobial Resistance in the elderly Vaccination as a potential strategy to combat Antimicrobial Resistance in the elderly Wilbur Chen, MD, MS 22-23 March 2017 WHO meeting on Immunization of the Elderly The Problem Increasing consumption

More information

Impact of Antimicrobial Resistance on Human Health. Robert Cunney HSE HCAI/AMR Programme and Temple Street Children s University Hospital

Impact of Antimicrobial Resistance on Human Health. Robert Cunney HSE HCAI/AMR Programme and Temple Street Children s University Hospital Impact of Antimicrobial Resistance on Human Health Robert Cunney HSE HCAI/AMR Programme and Temple Street Children s University Hospital AMR in Foodchain Conference, UCD, Dec 2014 Sir Patrick Dun s Hospital

More information

For Alberta broiler producers, the biggest impacts will be:

For Alberta broiler producers, the biggest impacts will be: Changes to Health Canada s Prescription Drug List: Getting Ready for Changes in Veterinary Oversight Requirements On December 1, 2018 prescription requirements for medically important antimicrobials come

More information

Recommendations for Implementation of Antimicrobial Stewardship Restrictive Interventions in Acute Hospitals in Ireland

Recommendations for Implementation of Antimicrobial Stewardship Restrictive Interventions in Acute Hospitals in Ireland Recommendations for Implementation of Antimicrobial Stewardship Restrictive Interventions in Acute Hospitals in Ireland A report by the Hospital Antimicrobial Stewardship Working Group, a subgroup of the

More information

MICRO-ORGANISMS by COMPANY PROFILE

MICRO-ORGANISMS by COMPANY PROFILE MICRO-ORGANISMS by COMPANY PROFILE 2017 1 SAPROPHYTES AND PATHOGENES SAPROPHYTES Not dangerous PATHOGENES Inducing diseases Have to be eradicated WHERE ARE THERE? EVERYWHERE COMPANY PROFILE 2017 3 MICROORGANISMS

More information

Horizontal vs Vertical Infection Control Strategies

Horizontal vs Vertical Infection Control Strategies GUIDE TO INFECTION CONTROL IN THE HOSPITAL Chapter 14 Horizontal vs Vertical Infection Control Strategies Author Salma Abbas, MBBS Michael Stevens, MD, MPH Chapter Editor Shaheen Mehtar, MBBS. FRC Path,

More information

Antibiotic Resistance

Antibiotic Resistance Preparing for the Battle Antibiotic Resistance Joy Jiao Systems Biology, Harvard University World Health Organization Global Report on Antibiotic Resistance, 01: resistance to common bacteria has reached

More information

Antibiotic resistance: the rise of the superbugs

Antibiotic resistance: the rise of the superbugs Antibiotic resistance: the rise of the superbugs Allen Cheng Associate Professor of Infectious Diseases Epidemiology, Alfred Health; Monash University About me Specialist in infectious diseases Head, Infection

More information

Evaluation of EU strategy to combat AMR

Evaluation of EU strategy to combat AMR Evaluation of EU strategy to combat AMR Advisory Group of the Food Chain 30 April 2015 Martial Plantady Legislative officer DDG2.G4: Food, Alert Systems & Training DG Health and Food Safety Antimicrobial

More information

Rise of the Superbugs: the end of antibiotics? Peter Lambert Life and Health Sciences Aston University

Rise of the Superbugs: the end of antibiotics? Peter Lambert Life and Health Sciences Aston University Rise of the Superbugs: the end of antibiotics? Peter Lambert Life and Health Sciences Aston University Willard Wigan Microbiologists grow bacteria on plates Each colony is formed from a single cell Colonies

More information

Overview of Infection Control and Prevention

Overview of Infection Control and Prevention Overview of Infection Control and Prevention Review of the Cesarean-section Antibiotic Prophylaxis Program in Jordan and Workshop on Rational Medicine Use and Infection Control Terry Green and Salah Gammouh

More information

Combating Antimicrobial Resistance: The Way Forward

Combating Antimicrobial Resistance: The Way Forward Combating Antimicrobial Resistance: The Way Forward James M. Hughes, MD Professor of Medicine and Public Health Emory University Atlanta, GA NIAA Antibiotic Symposium November 14, 2014 Disclosure No conflicts

More information

Typhoid fever - priorities for research and development of new treatments

Typhoid fever - priorities for research and development of new treatments Typhoid fever - priorities for research and development of new treatments Isabela Ribeiro, Manica Balasegaram, Christopher Parry October 2017 Enteric infections Enteric infections vary in symptoms and

More information

EVIDENCE BASED MEDICINE: ANTIBIOTIC RESISTANCE IN THE ELDERLY CHETHANA KAMATH GERIATRIC MEDICINE WEEK

EVIDENCE BASED MEDICINE: ANTIBIOTIC RESISTANCE IN THE ELDERLY CHETHANA KAMATH GERIATRIC MEDICINE WEEK EVIDENCE BASED MEDICINE: ANTIBIOTIC RESISTANCE IN THE ELDERLY CHETHANA KAMATH GERIATRIC MEDICINE WEEK EPIDEMIOLOGY AND BACKGROUND Every year, more than 2 million people in the United States acquire antibiotic-resistant

More information

What s happening across the UK with antimicrobial prescribing quality indicators?

What s happening across the UK with antimicrobial prescribing quality indicators? What s happening across the UK with antimicrobial prescribing quality indicators? Dr Jacqueline Sneddon, MRPharmS Project Lead, Scottish Antimicrobial Prescribing Group Antimicrobial Management Team Network

More information

Evaluating the Role of MRSA Nasal Swabs

Evaluating the Role of MRSA Nasal Swabs Evaluating the Role of MRSA Nasal Swabs Josh Arnold, PharmD PGY1 Pharmacy Resident Pharmacy Grand Rounds February 28, 2017 2016 MFMER slide-1 Objectives Identify the pathophysiology of MRSA nasal colonization

More information

Does Screening for MRSA Colonization Have A Role In Healthcare-Associated Infection Prevention Programs?

Does Screening for MRSA Colonization Have A Role In Healthcare-Associated Infection Prevention Programs? Does Screening for MRSA Colonization Have A Role In Healthcare-Associated Infection Prevention Programs? John A. Jernigan, MD, MS Division of Healthcare Quality Promotion Centers for Disease Control and

More information

2016/LSIF/FOR/003 Strengthening Surveillance and Laboratory Capacity to Fight Healthcare Associated Infections Antimicrobial Resistance

2016/LSIF/FOR/003 Strengthening Surveillance and Laboratory Capacity to Fight Healthcare Associated Infections Antimicrobial Resistance 2016/LSIF/FOR/003 Strengthening Surveillance and Laboratory Capacity to Fight Healthcare Associated Infections Antimicrobial Resistance Submitted by: Viet Nam Policy Forum on Strengthening Surveillance

More information

Global Status of Antimicrobial Resistance with a Focus on Nepal

Global Status of Antimicrobial Resistance with a Focus on Nepal Global Status of Antimicrobial Resistance with a Focus on Nepal John Ferguson, John Hunter Hospital, University of Newcastle, NSW, Australia Infectious Diseases Physician and Medical Microbiologist SIMON

More information

Multidrug-Resistant Organisms: How Do We Define them? How do We Stop Them?

Multidrug-Resistant Organisms: How Do We Define them? How do We Stop Them? Multidrug-Resistant Organisms: How Do We Define them? How do We Stop Them? Roberta B. Carey, PhD Centers for Disease Control and Prevention Division of Healthcare Quality Promotion Why worry? MDROs Clinical

More information

Multi-drug resistant microorganisms

Multi-drug resistant microorganisms Multi-drug resistant microorganisms Arzu TOPELI Director of MICU Hacettepe University Faculty of Medicine, Ankara-Turkey Council Member of WFSICCM Deaths in the US declined by 220 per 100,000 with the

More information

S aureus infections: outpatient treatment. Dirk Vogelaers Dept of Infectious Diseases University Hospital Gent Belgium

S aureus infections: outpatient treatment. Dirk Vogelaers Dept of Infectious Diseases University Hospital Gent Belgium S aureus infections: outpatient treatment Dirk Vogelaers Dept of Infectious Diseases University Hospital Gent Belgium Intern Med J. 2005 Feb;36(2):142-3 Intern Med J. 2005 Feb;36(2):142-3 Treatment of

More information

Antimicrobial stewardship in companion animals: Welcome to a whole new era

Antimicrobial stewardship in companion animals: Welcome to a whole new era Antimicrobial stewardship in companion animals: Welcome to a whole new era John F. Prescott, University Professor Emeritus, Department of Pathobiology, University of Guelph, Guelph, Ontario NG 2W1 prescott@uoguelph.ca

More information

Antibacterial Resistance: Research Efforts. Henry F. Chambers, MD Professor of Medicine University of California San Francisco

Antibacterial Resistance: Research Efforts. Henry F. Chambers, MD Professor of Medicine University of California San Francisco Antibacterial Resistance: Research Efforts Henry F. Chambers, MD Professor of Medicine University of California San Francisco Resistance Resistance Dose-Response Curve Antibiotic Exposure Anti-Resistance

More information

TREAT Steward. Antimicrobial Stewardship software with personalized decision support

TREAT Steward. Antimicrobial Stewardship software with personalized decision support TREAT Steward TM Antimicrobial Stewardship software with personalized decision support ANTIMICROBIAL STEWARDSHIP - Interdisciplinary actions to improve patient care Quality Assurance The aim of antimicrobial

More information

Antibiotic Stewardship in the LTC Setting

Antibiotic Stewardship in the LTC Setting Antibiotic Stewardship in the LTC Setting Joe Litsey, Director of Consulting Services Pharm.D., Board Certified Geriatric Pharmacist Thrifty White Pharmacy Objectives Describe the Antibiotic Stewardship

More information

Antimicrobial Resistance and Papua New Guinea WHY is it important? HOW has the problem arisen? WHAT can we do?

Antimicrobial Resistance and Papua New Guinea WHY is it important? HOW has the problem arisen? WHAT can we do? Antimicrobial Resistance and Papua New Guinea WHY is it important? HOW has the problem arisen? WHAT can we do? John Ferguson, John Hunter Hospital, University of Newcastle, NSW, Australia Infectious Diseases

More information

Antimicrobial Stewardship. Where are we now and where do we need to go?

Antimicrobial Stewardship. Where are we now and where do we need to go? Safe Patient Care Bugs and Drugs The ongoing challenge of MDROs and AMR 2017 @SPC2016Cork Antimicrobial Stewardship. Where are we now and where do we need to go? Frank O Riordan Antimicrobial pharmacist,

More information

The International Collaborative Conference in Clinical Microbiology & Infectious Diseases

The International Collaborative Conference in Clinical Microbiology & Infectious Diseases The International Collaborative Conference in Clinical Microbiology & Infectious Diseases PLUS: Antimicrobial stewardship in hospitals: Improving outcomes through better education and implementation of

More information

Antibiotics in the future tense: The Application of Antibiotic Stewardship in Veterinary Medicine. Mike Apley Kansas State University

Antibiotics in the future tense: The Application of Antibiotic Stewardship in Veterinary Medicine. Mike Apley Kansas State University Antibiotics in the future tense: The Application of Antibiotic Stewardship in Veterinary Medicine Mike Apley Kansas State University Changes in Food Animal Antibiotic Use How the uses of antibiotics in

More information

ANTIBIOTICS: TECHNOLOGIES AND GLOBAL MARKETS

ANTIBIOTICS: TECHNOLOGIES AND GLOBAL MARKETS ANTIBIOTICS: TECHNOLOGIES AND GLOBAL MARKETS PHM025D March 2016 Neha Maliwal Project Analyst ISBN: 1-62296-252-4 BCC Research 49 Walnut Park, Building 2 Wellesley, MA 02481 USA 866-285-7215 (toll-free

More information

Pathogens and Antibiotic Sensitivities in Post- Phacoemulsification Endophthalmitis, Kaiser Permanente, California,

Pathogens and Antibiotic Sensitivities in Post- Phacoemulsification Endophthalmitis, Kaiser Permanente, California, Pathogens and Antibiotic Sensitivities in Post- Phacoemulsification Endophthalmitis, Kaiser Permanente, California, 2007-2012 Geraldine R. Slean, MD, MS 1 ; Neal H. Shorstein, MD 2 ; Liyan Liu, MD, MS

More information

Stratégie et action européennes

Stratégie et action européennes Résistance aux antibiotiques : une impasse thérapeutique? Implications nationales et internationales Stratégie et action européennes Dominique L. Monnet, Senior Expert and Head of Disease Programme Antimicrobial

More information

running head: SUPERBUGS Humphreys 1

running head: SUPERBUGS Humphreys 1 running head: SUPERBUGS Humphreys 1 Superbugs GCH 360 Term Paper Assignment Kelly Humphreys April 30, 2014 SUPERBUGS Humphreys 2 Introduction The World Health Organization (WHO) recognizes antibiotic resistance

More information

Disclosure. Update on management of fungal keratitis. Acknowledgments. World Blindness 1993

Disclosure. Update on management of fungal keratitis. Acknowledgments. World Blindness 1993 Update on management of fungal keratitis Tom Lietman, MD F I Proctor Foundation Department of Ophthalmology University of California San Francisco Disclosure Voriconazole donated by Pfizer Natamycin and

More information

The importance of infection control in the era of multi drug resistance

The importance of infection control in the era of multi drug resistance Dr. Kumar Consultant Infectious Diseases Physician Hospital Sungai buloh The importance of infection control in the era of multi drug resistance Nosocomial infections In Australian acute hospitals 200,000

More information

REPORT ON THE ANTIMICROBIAL RESISTANCE (AMR) SUMMIT

REPORT ON THE ANTIMICROBIAL RESISTANCE (AMR) SUMMIT 1 REPORT ON THE ANTIMICROBIAL RESISTANCE (AMR) SUMMIT The Department of Health organised a summit on Antimicrobial Resistance (AMR) the purpose of which was to bring together all stakeholders involved

More information

Challenges and opportunities for rapidly advancing reporting and improving inpatient antibiotic use in the U.S.

Challenges and opportunities for rapidly advancing reporting and improving inpatient antibiotic use in the U.S. Challenges and opportunities for rapidly advancing reporting and improving inpatient antibiotic use in the U.S. Overview of benchmarking Antibiotic Use Scott Fridkin, MD, Senior Advisor for Antimicrobial

More information

Healthcare-associated infections surveillance report

Healthcare-associated infections surveillance report Healthcare-associated infections surveillance report Methicillin-resistant Staphylococcus aureus (MRSA) Update, Q3 of 2017/18 Summary Table Q3 2017/18 Previous quarter (Q2 2017/18) Same quarter of previous

More information

Quality indicators and outcomes in the devolved nations Scotland

Quality indicators and outcomes in the devolved nations Scotland Quality indicators and outcomes in the devolved nations Scotland Dr Jacqueline Sneddon, MRPharmS Project Lead, Scottish Antimicrobial Prescribing Group Federation of Infection Societies Conference Birmingham,

More information

11/22/2016. Antimicrobial Stewardship Update Disclosures. Outline. No conflicts of interest to disclose

11/22/2016. Antimicrobial Stewardship Update Disclosures. Outline. No conflicts of interest to disclose Antimicrobial Stewardship Update 2016 APIC-CI Conference November 17 th, 2016 Jay R. McDonald, MD Chief, ID Section VA St. Louis Health Care System Assistant Professor of medicine Washington University

More information

3/1/2016. Antibiotics --When Less is More. Most Urgent Threats. Serious Threats

3/1/2016. Antibiotics --When Less is More. Most Urgent Threats. Serious Threats Antibiotics --When Less is More Ralph Gonzales, MD, MSPH Associate Dean, Clinical Innovation School of Medicine VP, Clinical Innovation, UCSF Health Most Urgent Threats Serious Threats Multidrug-Resistant

More information

Corneal collagen cross-linking (CXL) for the treatment of melting keratitis in cats and dogs: a pilot study

Corneal collagen cross-linking (CXL) for the treatment of melting keratitis in cats and dogs: a pilot study Zurich Open Repository and Archive University of Zurich Main Library Strickhofstrasse CH-0 Zurich www.zora.uzh.ch Year: Corneal collagen cross-linking (CXL) for the treatment of melting keratitis in cats

More information

DR. BASHIRU BOI KIKIMOTO

DR. BASHIRU BOI KIKIMOTO OVERVIEW OF ANTIMICROBIAL RESISTANCE AND ANTIMICROBIAL USE IN GHANA PRESENTED BY : DR. BASHIRU BOI KIKIMOTO DVM. PhD VETERINARY PUBLIC HEALTH HEAD - PUBLIC HEALTH UNIT & FOOD SAFETY UNIT VENUE: SWATZILAND

More information

IFMSA Policy Proposal Antimicrobial Resistance

IFMSA Policy Proposal Antimicrobial Resistance IFMSA Policy Proposal Antimicrobial Resistance Proposed by Team of Officials Presented to the IFMSA General Assembly March Meeting 2017 in Arusha, Tanzania Policy Statement Introduction Antimicrobial resistance

More information

Antimicrobial Copper Touch Surfaces: A new tool for Infection Control and Prevention

Antimicrobial Copper Touch Surfaces: A new tool for Infection Control and Prevention Antimicrobial Copper Touch Surfaces: A new tool for Infection Control and Prevention Wilton Moran Project Engineer Copper Development Association The Science Behind the Technology Digital Summit Infection

More information

Why should we care about multi-resistant bacteria? Clinical impact and

Why should we care about multi-resistant bacteria? Clinical impact and Why should we care about multi-resistant bacteria? Clinical impact and public health implications Prof. Stephan Harbarth Infection Control Program Geneva, Switzerland and Ebola (in 2014/2015) Increased

More information

Introduction to Chemotherapeutic Agents. Munir Gharaibeh MD, PhD, MHPE School of Medicine, The university of Jordan November 2018

Introduction to Chemotherapeutic Agents. Munir Gharaibeh MD, PhD, MHPE School of Medicine, The university of Jordan November 2018 Introduction to Chemotherapeutic Agents Munir Gharaibeh MD, PhD, MHPE School of Medicine, The university of Jordan November 2018 Antimicrobial Agents Substances that kill bacteria without harming the host.

More information

MDRO s, Stewardship and Beyond. Linda R. Greene RN, MPS, CIC

MDRO s, Stewardship and Beyond. Linda R. Greene RN, MPS, CIC MDRO s, Stewardship and Beyond Linda R. Greene RN, MPS, CIC linda_greene@urmc.rochester.edu Evolving Threat of Antimicrobial Resistance Why are MDROs important? Limited treatment options Associated with:

More information

Dr Marc Sprenger Director Antimicrobial Resistance Secretariat Global action plan on antimicrobial resistance

Dr Marc Sprenger Director Antimicrobial Resistance Secretariat Global action plan on antimicrobial resistance Global Action Plan on Antimicrobial Resistance Dr Marc Sprenger Director Antimicrobial Resistance Secretariat When are we entering the post-antibiotic era? For some diseases we have already entered! Fatal

More information

Antibiotic Stewardship in the Hospital Setting

Antibiotic Stewardship in the Hospital Setting Antibiotic Stewardship in the Hospital Setting G. Evans, MD FRCPC Medical Director, Infection Prevention & Control Kingston General Hospital & Hotel Dieu Hospital EOPIC September 26, 2012 Stewardship stew-ard-ship

More information

Will 10 Million People Die a Year due to Antimicrobial Resistance by 2050? Prof. Stephan Harbarth Infection Control Program Geneva, Switzerland

Will 10 Million People Die a Year due to Antimicrobial Resistance by 2050? Prof. Stephan Harbarth Infection Control Program Geneva, Switzerland Will 10 Million People Die a Year due to Antimicrobial Resistance by 2050? Prof. Stephan Harbarth Infection Control Program Geneva, Switzerland Thanks for material provided by Marlieke de Kraker & Andrew

More information

Get Smart For Healthcare

Get Smart For Healthcare Get Smart For Healthcare Know When Antibiotics Work Marry Bardin, Quality Improvement Advisor June 9, 2015 Why We Need to Improve In-patient Antibiotic Use Antibiotics are misused in hospitals Antibiotic

More information

Antibiotic courses and antibiotic conservation, getting the balance right

Antibiotic courses and antibiotic conservation, getting the balance right Antibiotic courses and antibiotic conservation, getting the balance right Prof Martin Llewelyn Brighton and Sussex Medical School Brighton and Sussex University Hospitals NHS Trust The King's Fund: Ideas

More information

REVIEW OF OPHTHALMOLOGY SECTION OF WHO MODEL LIST OF ESSENTIAL MEDICINES. Sight Savers International and The Vision 2020 Technology Group

REVIEW OF OPHTHALMOLOGY SECTION OF WHO MODEL LIST OF ESSENTIAL MEDICINES. Sight Savers International and The Vision 2020 Technology Group REVIEW OF OPHTHALMOLOGY SECTION OF WHO MODEL LIST OF ESSENTIAL MEDICINES Anti infective agent Medicine suggested for inclusion Ciprofloxacin: 0.3 % eye drops Application submitted by Sight Savers International

More information

Optimizing Antimicrobial Stewardship Activities Based on Institutional Resources

Optimizing Antimicrobial Stewardship Activities Based on Institutional Resources Optimizing Antimicrobial Stewardship Activities Based on Institutional Resources Andrew Hunter, PharmD, BCPS Infectious Diseases Clinical Pharmacy Specialist Michael E. DeBakey VA Medical Center Andrew.hunter@va.gov

More information

Antibiotic resistance: how did we get here and what can we do? Peter Lambert LHS

Antibiotic resistance: how did we get here and what can we do? Peter Lambert LHS Antibiotic resistance: how did we get here and what can we do? Peter Lambert LHS How do we diagnose and treat infection? Organisms are cultured and identified Microscopy gives a clue to identity Staphylococcus

More information

Summary of the latest data on antibiotic resistance in the European Union

Summary of the latest data on antibiotic resistance in the European Union Summary of the latest data on antibiotic resistance in the European Union EARS-Net surveillance data November 2017 For most bacteria reported to the European Antimicrobial Resistance Surveillance Network

More information

Antibiotic Review Kit - Hospital

Antibiotic Review Kit - Hospital The International Convention Centre (ICC), Birmingham 11 12 September 2017 Antibiotic Review Kit - Hospital (ARK-hospital) Elizabeth Cross Brighton and Sussex University Hospitals NHS Trust Brighton and

More information

choice The Rilexine Palatable Tablets First generation cephalosporin for skin infections Now registered for ONCE daily administration*

choice The Rilexine Palatable Tablets First generation cephalosporin for skin infections Now registered for ONCE daily administration* Virbac Dermatology Palatable Tablets The choice First generation cephalosporin for skin infections Now registered for ONCE daily administration* are only available under Veterinary Authorisation. www.virbac.co.nz

More information

8/17/2016 ABOUT US REDUCTION OF CLOSTRIDIUM DIFFICILE THROUGH THE USE OF AN ANTIMICROBIAL STEWARDSHIP PROGRAM

8/17/2016 ABOUT US REDUCTION OF CLOSTRIDIUM DIFFICILE THROUGH THE USE OF AN ANTIMICROBIAL STEWARDSHIP PROGRAM Mary Moore, MS CIC MT (ASCP) Infection Prevention Coordinator Great River Medical Center, West Burlington REDUCTION OF CLOSTRIDIUM DIFFICILE THROUGH THE USE OF AN ANTIMICROBIAL STEWARDSHIP PROGRAM ABOUT

More information

Surveillance of AMR in PHE: a multidisciplinary,

Surveillance of AMR in PHE: a multidisciplinary, Surveillance of AMR in PHE: a multidisciplinary, integrated approach Professor Neil Woodford Antimicrobial Resistance & Healthcare Associated Infections (AMRHAI) Reference Unit Crown copyright International

More information

These life-saving drugs have been a boon to medical care and benefited hundreds of million patients around the globe.

These life-saving drugs have been a boon to medical care and benefited hundreds of million patients around the globe. SINCE Sir Alexander Fleming, a Scottish biologist, pharmacologist and botanist (a 1945 Nobel laureate), first discovered penicillin in 1923, hundreds of more potent wider spectrum antibiotics have been

More information

English Surveillance Programme for Antimicrobial Utilisation and Resistance (ESPAUR)

English Surveillance Programme for Antimicrobial Utilisation and Resistance (ESPAUR) English Surveillance Programme for Antimicrobial Utilisation and Resistance (ESPAUR) Berit Muller-Pebody HCAI & AMR Department, Centre for Infectious Disease Surveillance and Control Chief Medical Officer

More information

Clostridium Difficile Infection (CDI) Alistair McGregor Hobart Pathology Royal Hobart Hospital TIPCU

Clostridium Difficile Infection (CDI) Alistair McGregor Hobart Pathology Royal Hobart Hospital TIPCU Clostridium Difficile Infection (CDI) Alistair McGregor Hobart Pathology Royal Hobart Hospital TIPCU Disclosures I am not Tom Riley The Fidaxomicin guys brought me dinner once Outline ASID/AICA position

More information

Bacterial Keratitis Should optometrists treat in the community?

Bacterial Keratitis Should optometrists treat in the community? Case Record 13 Bacterial Keratitis Should optometrists treat in the community? December 2008 Dr Peter Frampton DOptom MSc FCOptom BAppSc(Optom)(AUS) DipTp(AS) DipTp(SP) DipTp(IP) Introduction Can Optometrists

More information

Antibacterial Agents & Conditions. Stijn van der Veen

Antibacterial Agents & Conditions. Stijn van der Veen Antibacterial Agents & Conditions Stijn van der Veen Antibacterial agents & conditions Antibacterial agents Disinfectants: Non-selective antimicrobial substances that kill a wide range of bacteria. Only

More information

The challenge of growing resistance

The challenge of growing resistance EXECUTIVE SUMMARY Around 2.4 million people could die in Europe, North America and Australia between 2015-2050 due to superbug infections unless more is done to stem antibiotic resistance. However, three

More information

03/09/2014. Infection Prevention and Control A Foundation Course. Talk outline

03/09/2014. Infection Prevention and Control A Foundation Course. Talk outline Infection Prevention and Control A Foundation Course 2014 What is healthcare-associated infection (HCAI), antimicrobial resistance (AMR) and multi-drug resistant organisms (MDROs)? Why we should be worried?

More information

Antibiotic Resistance in the Post-Acute and Long-Term Care Settings: Strategies for Stewardship

Antibiotic Resistance in the Post-Acute and Long-Term Care Settings: Strategies for Stewardship Antibiotic Resistance in the Post-Acute and Long-Term Care Settings: Strategies for Stewardship J. Hudson Garrett Jr., PhD, MSN, MPH, FNP-BC, PLNC, CDONA, IP-BC, GDCN, CDP, CADDCT, CALN, VA-BC, AS-BC,

More information

Development and improvement of diagnostics to improve use of antibiotics and alternatives to antibiotics

Development and improvement of diagnostics to improve use of antibiotics and alternatives to antibiotics Priority Topic B Diagnostics Development and improvement of diagnostics to improve use of antibiotics and alternatives to antibiotics The overarching goal of this priority topic is to stimulate the design,

More information

Redefining Infection Management. Proven Clinical Outcomes

Redefining Infection Management. Proven Clinical Outcomes Proven Clinical Outcomes Proof of Bacteria-Binding1 In the first 30 seconds, 1 square centimeter of Cutimed Sorbact binds wound bacteria - after 2 hours, the amount of bacteria bound are more than would

More information

Antimicrobial Resistance and One Health: Research Needs

Antimicrobial Resistance and One Health: Research Needs Antimicrobial Resistance and One Health: Research Needs Amelia Woolums, DVM PhD DACVIM DACVM College of Veterinary Medicine, Mississippi State University amelia.woolums@msstate.edu Why do we use antimicrobials?

More information

Antibiotic treatment in the ICU 1. ICU Fellowship Training Radboudumc

Antibiotic treatment in the ICU 1. ICU Fellowship Training Radboudumc Antibiotic treatment in the ICU 1 ICU Fellowship Training Radboudumc Main issues Delayed identification of microorganisms Impact of critical illness on Pk/Pd High prevalence of antibiotic resistant strains

More information

Responsible use of antibiotics

Responsible use of antibiotics Responsible use of antibiotics Uga Dumpis MD, PhD Department of Infectious Diseases and Infection Control Pauls Stradiņs Clinical University Hospital Challenges in the hospitals Antibiotics are still effective

More information

Antimicrobial stewardship: Quick, don t just do something! Stand there!

Antimicrobial stewardship: Quick, don t just do something! Stand there! Antimicrobial stewardship: Quick, don t just do something! Stand there! Stanley I. Martin, MD, FACP, FIDSA Director, Division of Infectious Diseases Director, Antimicrobial Stewardship Program Geisinger

More information

USA ACTION PLAN FOR COMBATING ANTIBIOTIC-RESISTANT BACTERIA

USA ACTION PLAN FOR COMBATING ANTIBIOTIC-RESISTANT BACTERIA FMM/RAS/298: Strengthening capacities, policies and national action plans on prudent and responsible use of antimicrobials in fisheries Final Workshop in cooperation with AVA Singapore and INFOFISH 12-14

More information

ANTIMICROBIAL STEWARDSHIP

ANTIMICROBIAL STEWARDSHIP ANTIMICROBIAL STEWARDSHIP Australian Pig Veterinarians Annual Conference 11-12 September, 2017 Stephen Page Advanced Veterinary Therapeutics swp@advet.com.au OUTLINE Importance of AMR Antimicrobial use

More information

Scottish Medicines Consortium

Scottish Medicines Consortium Scottish Medicines Consortium tigecycline 50mg vial of powder for intravenous infusion (Tygacil ) (277/06) Wyeth 9 June 2006 The Scottish Medicines Consortium (SMC) has completed its assessment of the

More information

Antimicrobial Resistance Update for Community Health Services

Antimicrobial Resistance Update for Community Health Services Antimicrobial Resistance Update for Community Health Services Elizabeth Beech Healthcare Acquired Infection and Antimicrobial Resistance Project Lead NHS England October 2015 elizabeth.beech@nhs.net Superbugs

More information

Selective toxicity. Antimicrobial Drugs. Alexander Fleming 10/17/2016

Selective toxicity. Antimicrobial Drugs. Alexander Fleming 10/17/2016 Selective toxicity Antimicrobial Drugs Chapter 20 BIO 220 Drugs must work inside the host and harm the infective pathogens, but not the host Antibiotics are compounds produced by fungi or bacteria that

More information

Dr. P. P. Doke. M.D., D.N.B., Ph.D., FIPHA. Professor, Department of Community Medicine, Bharati Vidyapeeth Medical College, Pune

Dr. P. P. Doke. M.D., D.N.B., Ph.D., FIPHA. Professor, Department of Community Medicine, Bharati Vidyapeeth Medical College, Pune Dr. P. P. Doke M.D., D.N.B., Ph.D., FIPHA Professor, Department of Community Medicine, Bharati Vidyapeeth Medical College, Pune 1 Anti microbial resistance is now a global geometrically increasing threat

More information

Why Don t These Drugs Work Anymore? Biosciences in the 21 st Century Dr. Amber Rice October 28, 2013

Why Don t These Drugs Work Anymore? Biosciences in the 21 st Century Dr. Amber Rice October 28, 2013 Why Don t These Drugs Work Anymore? Biosciences in the 21 st Century Dr. Amber Rice October 28, 2013 Outline Drug resistance: a case study Evolution: the basics How does resistance evolve? Examples of

More information